Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing from China

Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing from China
Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing from China Company’s stock among those that gained substantially during COVID-19 days. Drug maker planning contract manufacturing of specialty products. Other Indian pharma companies also benefit as buyers, both domestic and global, scout for non-Chinese suppliers of raw materials.